Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating a new medicine called PF-08634404 in adults with advanced Renal Cell Carcinoma RCC, a type of kidney cancer that has spread locally or to other parts of the body. This study aims to assess the safety of PF-08634404 given alone or combined with other anticancer drugs and to observe how the cancer responds. Participants must be adults with locally advanced or metastatic RCC who have not received treatment for advanced kidney cancer before joining. Participants will be randomly assigned to receive one of four treatments PF-08634404 alone, PF-08634404 with ipilimumab, PF-08634404 with axitinib, or PF-08634404 with Casdatifan. All medications are administered through intravenous infusions or tablets as appropriate, given at clinical study sites by trained medical staff. The study includes treatment and evaluation phases lasting up to approximately three years. During the study, participants will have regular assessments including scans following RECIST v1.1 guidelines to measure tumor response. Researchers will monitor treatment safety by tracking adverse events, dose-limiting toxicities, and laboratory test results. Pharmacokinetics and immune response to the study drug will also be evaluated. These measures will continue through treatment and up to 90 days after the last intervention, with follow-up for up to three years to assess overall survival and progression-free survival.
Actively Recruiting
Researchers are studying advanced or recurrent endometrial cancer that has a functioning mismatch repair system, called pMMR. This cancer type is harder for the immune system to attack. The study compares a new medicine, PF-08634404, combined with chemotherapy, against pembrolizumab plus chemotherapy. It aims to see if the new combination improves outcomes for women with this type of endometrial cancer. Participants receive intravenous infusions of their assigned treatment in cycles. One group receives PF-08634404 plus chemotherapy followed by PF-08634404 alone for up to 2 years, while the other group receives pembrolizumab plus chemotherapy followed by pembrolizumab alone for up to 2 years. About 600 adult women will be randomly assigned to these groups in an open-label design where both patients and doctors know the treatment. Participants attend regular visits for treatment and health assessments. Cancer response is checked every 9 weeks for about 2 years, then every 12 weeks afterward. Follow-up continues every 12 weeks by phone, in person, or health record review. Researchers measure progression-free survival, overall survival, treatment responses, safety, quality of life, and other health outcomes during and after treatment.
Actively Recruiting
Researchers are evaluating the new medicine PF-08634404 in combination with chemotherapy compared to the current standard treatment pembrolizumab with chemotherapy for adults with locally advanced or metastatic non-small cell lung cancer NSCLC. The study includes adults with Stage IIIBIIIC or Stage IV squamous or non-squamous NSCLC who are not candidates for surgery or curative chemoradiotherapy and have not received prior treatment for advanced disease. Participants are assigned to two parts based on tumor type squamous NSCLC Part 1 or non-squamous NSCLC Part 2. Each participant is randomly assigned to receive either PF-08634404 or pembrolizumab with chemotherapy followed by maintenance therapy. Treatment is given through intravenous infusions in cycles, continuing as long as it is effective and safe. Different chemotherapy regimens are used depending on the tumor type. Throughout the study, participants attend regular visits for treatment and health monitoring. Cancer response is assessed every 6 weeks for the first 48 weeks and then every 12 weeks. Researchers will measure overall survival, progression-free survival, objective response rates, duration of response, adverse events, laboratory results, drug levels, immune response, and quality of life using questionnaires. The study lasts up to approximately 39 months with ongoing safety and effectiveness evaluations.